Urate Urolithiasis

Urate urolithiasis is a condition characterized by the formation of uroliths (stones) composed primarily of uric acid and its salts (ammonium urate, sodium urate, or calcium urate) within the urinary tract, most commonly affecting the bladder and urethra, but also potentially involving the kidneys and ureters. In veterinary medicine, urate stones are particularly significant in Dalmatians due to a genetic defect in hepatic uric acid metabolism, and in cats with portosystemic vascular anomalies (PSS) or other causes of hyperammonemia. The condition leads to lower urinary tract signs such as dysuria, hematuria, and stranguria, and can progress to urethral obstruction, a life-threatening emergency. Urate urolithiasis is classified based on the predominant crystalline component, with ammonium urate being the most common form in dogs and cats. The disease is often associated with underlying metabolic or hepatic abnormalities, and management requires both medical dissolution and surgical or interventional removal, along with dietary and pharmacological prevention.

The primary etiology of urate urolithiasis is hyperuricosuria, leading to supersaturation of urine with uric acid and subsequent crystallization. In Dalmatians, a breed-specific autosomal recessive trait causes defective hepatic uric acid transport, resulting in high urinary uric acid excretion. In other breeds and in cats, urate stones are frequently secondary to portosystemic shunts (PSS) or severe hepatic insufficiency, which impair the urea cycle and lead to hyperammonemia and hyperuricemia. Other causes include inherited enzyme deficiencies (e.g., xanthine oxidase deficiency), high-purine diets, and certain metabolic disorders. In cats, urate uroliths are often associated with congenital PSS, but can also occur in cats with chronic liver disease. Additionally, urate stones can form in animals with chronic dehydration, acidic urine pH, and low urine volume, which promote uric acid precipitation. In some cases, no underlying cause is identified (idiopathic hyperuricosuria).

Urate urolithiasis is most commonly diagnosed in Dalmatian dogs, with a reported incidence of up to 34% in this breed. The condition is also seen in other breeds, including English Bulldogs, Black Russian Terriers, and Miniature Schnauzers, often in association with PSS. In cats, urate uroliths account for approximately 5-10% of all feline uroliths, with a higher prevalence in young cats with congenital PSS. There is no strong sex predilection in dogs, but in cats, males may be slightly overrepresented due to their narrower urethra, which increases the risk of obstruction. The age of onset varies: Dalmatians typically present between 1 and 6 years of age, while cats with PSS often present under 1 year of age. Geographic distribution is not a major factor, but dietary practices and genetic lines may influence prevalence.

Urate urolithiasis develops when urine becomes supersaturated with uric acid or its salts. In Dalmatians, a genetic defect in the SLC2A9 gene (a urate transporter) leads to reduced hepatic uptake of uric acid and increased renal excretion, resulting in hyperuricosuria. In animals with PSS, portosystemic shunting bypasses the liver, causing reduced hepatic metabolism of ammonia and uric acid, leading to hyperammonemia and hyperuricemia. The kidneys filter excess uric acid, and in the distal tubules and collecting ducts, uric acid can precipitate when urine pH is acidic (typically <5.5) and urine concentration is high. Ammonium urate crystals form when ammonia and uric acid combine, especially in alkaline urine, but in dogs, urate stones often form in acidic urine. The crystals aggregate to form uroliths, which can cause mechanical irritation to the urothelium, leading to hematuria, inflammation, and secondary bacterial infection. Urethral obstruction can occur when stones lodge in the urethra, causing post-renal azotemia, bladder distension, and potentially rupture. Chronic inflammation may lead to fibrosis and bladder wall thickening.

Predisposing factors for urate urolithiasis include breed (Dalmatian, English Bulldog, Black Russian Terrier), congenital portosystemic shunts, hepatic insufficiency, high-purine diets (e.g., organ meats, certain fish), low water intake, acidic urine pH, and decreased urine volume. In Dalmatians, the genetic defect is the primary factor, but dietary purine load and urine pH modulate stone formation. In cats, PSS is the most common predisposing factor, but other causes of hyperammonemia (e.g., hepatic lipidosis, portosystemic shunting) can also contribute. Additionally, medications that increase uric acid excretion (e.g., some diuretics) or decrease urine pH (e.g., urinary acidifiers) may increase risk. Concurrent urinary tract infections with urease-producing bacteria can alkalinize urine and promote struvite formation, but urate stones are typically sterile.

Clinical signs of urate urolithiasis are primarily related to lower urinary tract irritation and obstruction. In early stages, animals may show hematuria, pollakiuria, dysuria, and stranguria. As stones enlarge or obstruct the urethra, signs progress to anuria, abdominal distension, vomiting, lethargy, and anorexia. In cats, urethral obstruction is a common emergency, presenting with vocalization, straining, and collapse. Physical examination may reveal a painful, distended bladder, and in cases of complete obstruction, signs of uremia (e.g., oral ulceration, hypothermia, bradycardia). In animals with PSS, additional signs such as ptyalism, seizures, and stunted growth may be present. Chronic cases may lead to bladder wall thickening and recurrent urinary tract infections.

Differential diagnoses for urate urolithiasis include other types of uroliths (struvite, calcium oxalate, cystine, silica), urinary tract infections (bacterial cystitis), neoplasia of the urinary bladder (e.g., transitional cell carcinoma), idiopathic cystitis (feline interstitial cystitis), and urethral plugs. Key distinguishing features: Struvite stones are typically radiopaque and often associated with urease-positive bacterial infections; calcium oxalate stones are also radiopaque and occur in acidic urine; cystine stones are radiolucent and occur in certain breeds (e.g., English Bulldogs, Newfoundlands); silica stones are radiopaque and associated with high-cereal diets. Urinary tract infections are diagnosed via urine culture and cytology. Bladder neoplasia is more common in older dogs and may be identified on imaging (e.g., irregular mass) and confirmed by biopsy. Idiopathic cystitis is a diagnosis of exclusion, often with no identifiable uroliths or infection. Urethral plugs are more common in male cats and consist of matrix material with crystals.

The diagnostic approach to suspected urate urolithiasis begins with a thorough history and physical examination, including abdominal palpation. Initial laboratory tests include complete blood count, serum biochemistry (including renal parameters, liver enzymes, bile acids), and urinalysis with urine sediment examination. Urine pH is typically acidic (<6.0) in urate stones. Imaging is essential: abdominal radiography may show radiolucent stones (urate stones are radiolucent, so they are not visible on plain radiographs), but contrast studies (pneumocystography or double-contrast cystography) can outline them. Ultrasonography is highly sensitive for detecting uroliths in the bladder and urethra, and can also assess for PSS (via hepatic ultrasonography). If PSS is suspected, bile acid stimulation testing and advanced imaging (CT angiography) are indicated. Definitive diagnosis is made by stone analysis (e.g., X-ray diffraction or infrared spectroscopy) after retrieval via voiding, catheterization, or surgery. In cases of urethral obstruction, emergency stabilization and decompression are performed before further diagnostics.

Hematology: May be normal, but in cases of chronic disease or PSS, microcytosis (due to iron deficiency) and target cells may be seen. Serum biochemistry: In uncomplicated cases, renal parameters are normal; however, in obstructive disease, azotemia (elevated BUN and creatinine) may be present. Liver enzymes may be elevated in PSS (e.g., ALT, ALP), and bile acids are typically increased. Hyperammonemia may be present in PSS. Urinalysis: Urine specific gravity is often concentrated (>1.030) unless renal disease is present. Urine pH is usually acidic (5.5-6.5). Hematuria and proteinuria may be present. Urine sediment may show urate crystals (amorphous or rhomboid, yellow-brown). Urine culture is recommended to rule out secondary infection. Blood gas analysis may reveal metabolic acidosis in cases of obstruction. Specific biomarkers: In PSS, serum bile acids (fasting and post-prandial) are elevated. SDMA may be normal unless renal dysfunction is present.

Radiography: Plain abdominal radiographs are often unremarkable because urate stones are radiolucent. However, they may be visible if mixed with calcium salts. Pneumocystography or double-contrast cystography can delineate filling defects. Ultrasonography: This is the preferred imaging modality for detecting urate uroliths, which appear as hyperechoic foci with acoustic shadowing. Ultrasound can also assess bladder wall thickness, detect urethral stones (via transabdominal or transrectal approach), and evaluate the liver for PSS (e.g., small liver, abnormal vessels). Computed Tomography (CT): CT is excellent for detecting radiolucent stones and for evaluating PSS (CT angiography). Magnetic Resonance Imaging (MRI): Not routinely used for urolithiasis but may be helpful in PSS evaluation. Endoscopy: Cystoscopy can be used to visualize stones and perform laser lithotripsy or basket retrieval. Fluoroscopy: Useful during interventional procedures.

Cytology: Fine-needle aspiration of bladder masses is not typically performed for uroliths, but urine sediment cytology may show crystals and inflammatory cells. Histopathology: If bladder wall biopsy is obtained (e.g., during surgery), it may show chronic cystitis with epithelial hyperplasia, fibrosis, and mononuclear inflammation. In PSS, liver biopsy may show hepatic microvascular dysplasia or portal hypoplasia. Stone analysis (by X-ray diffraction or infrared spectroscopy) is the gold standard for confirming urate composition.

Treatment of urate urolithiasis involves three main goals: relief of obstruction, elimination of existing stones, and prevention of recurrence. In cases of urethral obstruction, emergency management includes fluid therapy (e.g., 0.9% NaCl or lactated Ringer's solution at 10-20 ml/kg IV bolus, then 5-10 ml/kg/hr), bladder decompression via cystocentesis or urethral catheterization, and correction of electrolyte and acid-base imbalances. Once stabilized, stone removal can be achieved via medical dissolution or surgical/interventional methods. Medical dissolution is possible for urate stones using a low-purine diet (e.g., Hill's Prescription Diet u/d, Royal Canin Urinary UC Low Purine), urinary alkalinization (e.g., potassium citrate at 50-75 mg/kg PO q12h to maintain urine pH 6.5-7.0), and xanthine oxidase inhibitors (allopurinol at 10-20 mg/kg PO q12h for dissolution, or 10 mg/kg q24h for prevention). However, medical dissolution is slow (weeks to months) and not recommended for obstructing stones. Surgical removal (cystotomy) is the standard for large stones. Interventional options include laser lithotripsy and basket retrieval via cystoscopy. For animals with PSS, surgical attenuation of the shunt is the definitive treatment, which may resolve hyperuricosuria. Supportive care includes antibiotics for secondary infections, anti-inflammatories (e.g., meloxicam at 0.1 mg/kg PO q24h for 3-5 days), and increased water intake (e.g., canned food, subcutaneous fluids).

The prognosis for urate urolithiasis is generally good with appropriate treatment, but it depends on the underlying cause. In Dalmatians with no other disease, the prognosis is excellent if dietary and pharmacological prevention are followed, though recurrence is common if compliance is poor. In animals with PSS, the prognosis is guarded to good depending on the severity of the shunt and surgical success. Urethral obstruction carries a guarded prognosis if not treated promptly, with a mortality rate of up to 20-30% in cats. Negative prognostic indicators include severe azotemia, hyperkalemia, and delayed treatment. With proper management, most animals can live a normal life, but lifelong monitoring and dietary adherence are essential.

Follow-up care for urate urolithiasis includes re-evaluation at 1, 3, 6, and 12 months after initial treatment, then every 6-12 months thereafter. At each visit, perform urinalysis (including pH, specific gravity, sediment for crystals), urine culture if infection is suspected, and imaging (ultrasound or radiographs) to monitor for recurrence. In Dalmatians, monitor urine uric acid-to-creatinine ratio to assess control. For animals on allopurinol, monitor for xanthine stones (a potential side effect) and adjust dosage based on urine pH and stone recurrence. For animals with PSS, monitor liver function (bile acids) and clinical signs. Dietary compliance is critical; recommend a low-purine diet and encourage water intake. If recurrence occurs, re-evaluate for underlying causes and consider advanced imaging for PSS.

Pearls: 1) Urate stones are radiolucent, so always use ultrasound or contrast radiography for diagnosis. 2) In Dalmatians, urine pH should be maintained between 6.5 and 7.0 to prevent urate crystallization. 3) Allopurinol is effective but can cause xanthine stones if urine is too alkaline or if the dose is too high. 4) In cats with urate stones, always rule out PSS, especially in young cats. 5) Medical dissolution is feasible for non-obstructing stones, but surgical removal is faster and more reliable. Pitfalls: 1) Failing to check for PSS in non-Dalmatian dogs and cats with urate stones. 2) Using urinary acidifiers (e.g., methionine) which can worsen urate stone formation. 3) Not addressing underlying hepatic disease, leading to recurrence. 4) Overlooking secondary bacterial infections, which can complicate treatment. 5) Inadequate pain management after surgery.

Allopurinol (Zyloric): For dissolution of urate stones: 10-20 mg/kg PO q12h for 3-4 weeks, then reduce to 10 mg/kg q24h for prevention. For prevention: 10 mg/kg PO q24h. Adjust dose in renal impairment (reduce by 50% if creatinine >2.5 mg/dl). Contraindicated in animals with severe hepatic disease. Potassium citrate: 50-75 mg/kg PO q12h, titrate to maintain urine pH 6.5-7.0. Monitor for hyperkalemia. Antibiotics: If secondary infection, use appropriate antibiotics based on culture and sensitivity (e.g., amoxicillin-clavulanate 12.5-25 mg/kg PO q12h for 10-14 days). Anti-inflammatories: Meloxicam 0.1 mg/kg PO q24h for 3-5 days, or carprofen 2.2 mg/kg PO q12h for 3-5 days. For urethral obstruction, consider alpha-blockers (e.g., prazosin 0.25-0.5 mg/kg PO q8-12h) to relax urethral smooth muscle. Fluid therapy: 0.9% NaCl or lactated Ringer's solution at 10-20 ml/kg IV bolus, then 5-10 ml/kg/hr until hydration is restored. For hyperkalemia, treat with 10% calcium gluconate 0.5-1 ml/kg IV over 10-20 minutes, and regular insulin 0.1-0.2 U/kg IV with dextrose 2 g/U insulin.

Key studies: 1) Bartges et al. (1999) demonstrated that medical dissolution of urate uroliths in Dalmatians is effective with a low-purine diet and allopurinol, with a success rate of 80-90% over 2-3 months. 2) A study by Lulich et al. (2016) in cats showed that urate uroliths are strongly associated with PSS, and surgical attenuation of the shunt reduces recurrence. 3) The ACVIM Consensus Statement on Uroliths (2016) recommends that urate stones be managed with dietary modification, urinary alkalinization, and allopurinol, and emphasizes the importance of identifying underlying hepatic disease. 4) A retrospective study by Osborne et al. (2009) reported that Dalmatians with urate stones have a high recurrence rate (up to 50% within 1 year) if dietary compliance is poor. 5) Recent research on the SLC2A9 gene in Dalmatians has identified the genetic basis for hyperuricosuria, opening avenues for genetic testing and selective breeding.